Immunitybio Stock Filter Stocks by Fundamentals
| IBRX Stock | USD 3.01 0.02 0.67% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Immunitybio's long-term financial health and intrinsic value.
Immunitybio | Shares Owned by Insiders | Build AI portfolio with Immunitybio Stock |
Immunitybio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunitybio from analyzing Immunitybio's financial statements. These drivers represent accounts that assess Immunitybio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunitybio's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 5.1B | 2.4B | 2.0B | 2.6B | 2.9B | 2.7B | |
| Enterprise Value | 5.3B | 2.8B | 2.6B | 3.0B | 3.5B | 2.8B |
Immunitybio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunitybio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunitybio's managers, analysts, and investors.Environmental | Governance | Social |
Immunitybio Institutional Holders
Institutional Holdings refers to the ownership stake in Immunitybio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunitybio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunitybio's value.| Shares | Charles Schwab Investment Management Inc | 2025-03-31 | 1.3 M | Goldman Sachs Group Inc | 2025-03-31 | 1.1 M | Jpmorgan Chase & Co | 2025-03-31 | 1 M | Bsc Private Wealth Management, Llc | 2025-03-31 | 846.4 K | Verition Fund Managegment, Llc | 2025-03-31 | 827 K | Susquehanna International Group, Llp | 2025-03-31 | 773.5 K | Allen Holding Inc | 2025-03-31 | 687.6 K | Sheets Smith Wealth Management | 2025-06-30 | 633.5 K | Accurate Wealth Management, Llc | 2025-03-31 | 560 K | Vanguard Group Inc | 2025-03-31 | 20.3 M | Blackrock Inc | 2025-03-31 | 13.3 M |
Immunitybio Fundamentals
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.90) % | ||||
| Current Valuation | 2.86 B | ||||
| Shares Outstanding | 882.62 M | ||||
| Shares Owned By Insiders | 74.11 % | ||||
| Shares Owned By Institutions | 9.33 % | ||||
| Number Of Shares Shorted | 76.96 M | ||||
| Price To Sales | 76.61 X | ||||
| Revenue | 14.74 M | ||||
| Gross Profit | 31.16 M | ||||
| EBITDA | (241.76 M) | ||||
| Net Income | (413.64 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 504.17 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.69) X | ||||
| Cash Flow From Operations | (391.24 M) | ||||
| Short Ratio | 7.48 X | ||||
| Earnings Per Share | (0.57) X | ||||
| Price To Earnings To Growth | 3.69 X | ||||
| Target Price | 11.4 | ||||
| Number Of Employees | 671 | ||||
| Beta | -0.063 | ||||
| Market Capitalization | 2.39 B | ||||
| Total Asset | 382.93 M | ||||
| Retained Earnings | (3.38 B) | ||||
| Working Capital | 129.64 M | ||||
| Net Asset | 382.93 M |
About Immunitybio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VALE | Vale SA ADR | |
| EGY | Vaalco Energy | |
| CMCSA | Comcast Corp |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.